Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastritis Clear all
Terminated No phase listed Observational

Helicobacter Pylori Genome Project (HpGP)

NCT02788214
View directory record Official record
Conditions
Gastric Cancer, Non-Atrophic Gastritis, Intestinal Metaplasia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 70 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Batesville, Arkansas • Stanford, California • Athens, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

NCT03664960
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

NCT00477880
View directory record Official record
Conditions
Gastric Cancer, Precancerous Condition
Interventions
Cetuximab
Biological
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 21, 2026, 5:49 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

NCT02246439
View directory record Official record
Conditions
Gastroenteritis, Gastritis
Interventions
RHB-102, Placebo Oral Tablet
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
12 Years to 85 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Bakersfield, California • Sacramento, California • Sylmar, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04724291
View directory record Official record
Conditions
Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions
MAGNET
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 4 Interventional

Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2

NCT07224048
View directory record Official record
Conditions
H. Pylori Infection, Gastric Cancer, Gastritis H Pylori
Interventions
PYTEST® 14C-Urea Capsule Breath Test (at Home), PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 21, 2026, 5:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Data Bank for Eosinophilic Disorders

NCT00267475
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastritis, Enteritis, Eosinophilic Colitis, Eosinophilic Gastroenteritis
Interventions
Not listed
Lead sponsor
Marc Rothenberg
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting No phase listed Observational

The GAstric Precancerous Conditions Study

NCT04191551
View directory record Official record
Conditions
Gastric Cancer, Intestinal Metaplasia of Gastric Mucosa, Helicobacter Pylori Infection, Atrophic Gastritis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 84 Years
Enrollment
600 participants
Timeline
2018 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Family Members at INcreased-risk for Developing Inflammatory Bowel Disease

NCT06655415
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U), Indeterminate Colitis, Crohn's Disease Colon, Crohn's Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis, Ulcerative Proctitis, Ulcerative Proctosigmoiditis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting No phase listed Observational

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

NCT02523118
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2051
U.S. locations
19
States / cities
Phoenix, Arizona • Rogers, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Withdrawn No phase listed Observational

Eosinophilic Gastrointestinal Disorders Patient Registry

NCT01779154
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Benralizumab for Eosinophilic Gastritis (BEGS)

NCT03473977
View directory record Official record
Conditions
Eosinophilic Gastritis or Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 21, 2026, 5:49 PM EDT
Enrolling by invitation No phase listed Observational

UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study

NCT05021029
View directory record Official record
Conditions
Intestinal Metaplasia, Chronic Gastritis, Atrophic Gastritis, Autoimmune Gastritis, Intestinal Dysplasia, Gastric Polyps
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed No phase listed Observational

Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

NCT02897271
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • Denver, Colorado • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 5:49 PM EDT
Completed No phase listed Observational

Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)

NCT00212225
View directory record Official record
Conditions
Helicobacter Infections, Gastritis, Peptic Ulcer
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

NCT05251909
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Dupilumab in Eosinophilic Gastritis

NCT03678545
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Dupilumab (blinded), Placebo (blinded)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Active, not recruiting Phase 2 Interventional

Vedolizumab for the Treatment of Collagenous Gastritis

NCT06317220
View directory record Official record
Conditions
Collagenous Gastritis
Interventions
Vedolizumab
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Withdrawn Phase 3 Interventional

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

NCT05152563
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
76
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 21, 2026, 5:49 PM EDT
Completed No phase listed Observational

Registry for Eosinophilic Gastrointestinal Disorders (REGID)

NCT01382563
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGID), Eosinophilic Esophagitis, Eosinophilic Disorder
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 12 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

NCT05332639
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis
Interventions
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool, Standard Crohn's Disease Education
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 21, 2026, 5:49 PM EDT